SkinHealth Systems Inc Dossier - Source-backed chat

SkinHealth Systems Inc

SKINNASDAQ

SectorConsumer Staples

IndustryPersonal Care Products

Beta (adjusted)0.98

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $0.63Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $82M

Enterprise Value $239.3M

Shares Outstanding 123.9M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

SkinHealth Systems Inc. (formerly The Beauty Health Company) is undergoing a significant strategic transition under CEO Pedro Malha, shifting from a high-growth capital equipment model to a clinically driven, science-backed medical aesthetics platform. While the company's recurring consumables model remains highly durable and gross margins are robust (68.5% GAAP in Q1 2026), persistent weakness in capital equipment demand and device placements has pressured the top line, leading to a downward revision of full-year 2026 revenue guidance to $280M-$295M. However, disciplined cost management has kept adjusted EBITDA guidance steady at $35M-$45M. The stock is currently facing delisting risks due to trading below the $1.00 Nasdaq minimum bid price, making a 'Hold' recommendation appropriate until commercial execution stabilizes and device sales show signs of recovery.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.00

Mean target$1.34

High · most bullish analyst$2.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5520%

Capital equipment demand deteriorates further due to macroeconomic headwinds and credit constraints, dragging down consumables attach rates. The company fails to regain Nasdaq compliance, leading to delisting or highly dilutive financing. Turnaround initiatives under the new management take longer than expected, delaying a return to growth beyond 2027.

Base CaseCentral scenario

$1.3460%

Matches the consensus mean

The company achieves its revised FY 2026 revenue guidance of $280M-$295M and meets its adjusted EBITDA target of $35M-$45M through continued cost discipline. Device placements stabilize at lower levels while consumables provide a steady, high-margin recurring revenue stream. Nasdaq compliance is resolved, likely via a reverse stock split if organic recovery is insufficient.

Bull CaseUpside scenario

$2.0020%

A successful turnaround driven by the corporate rebranding to SkinHealth Systems and a sharper focus on clinical validation. Consumables utilization accelerates globally, offsetting weak device sales. The company successfully regains Nasdaq compliance organically, and the launch of next-generation Hydrafacial devices targeted for 2028 drives a strong return to growth.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong recurring revenue model with consumables representing a significant portion of the sales mix.
Robust gross margins (GAAP gross margin of 68.5% and adjusted gross margin of 72.2% in Q1 2026).
Substantial active installed base of over 36,400 devices globally, providing a solid foundation for consumable pull-through.
Disciplined cost management and operating expense reductions, keeping adjusted EBITDA guidance intact despite lower revenue.

Key Investment Risks

Persistent weakness in capital equipment demand and declining year-over-year device placements.
Nasdaq minimum bid price non-compliance, with a delisting deadline of November 4, 2026.
Intense competition in the medical aesthetics and skincare device markets.
Execution risk associated with the ongoing corporate turnaround and rebranding strategy.

Thesis Invalidation Triggers

Failure to meet the revised FY 2026 revenue guidance of $280M-$295M.
Adjusted EBITDA falling below the guided range of $35M-$45M.
Delisting from the Nasdaq Stock Market due to failure to regain compliance with the minimum bid price.
A material decline in active installed base utilization or consumables revenue.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.